Sign In
Buy ALBO
$44.15
+0 (+0%)
At Close: May 26, 2023
Albireo Energy Earns Great Place To Work Certification™ for Eighth Consecutive Year
07:30am, Thursday, 18'th Dec 2025
EDISON, N.J.--(BUSINESS WIRE)--Albireo Energy, a leading independent building controls and energy services provider and Huron Capital portfolio company, has been Certified™ by Great Place To Work®
Albireo Energy Names Mergers and Acquisitions Executive
07:00am, Thursday, 04'th Dec 2025
EDISON, N.J.--(BUSINESS WIRE)--Albireo Energy, a leading independent building controls and energy services provider and a Huron Capital portfolio company, today announced the appointment of Brad Freem
Albireo Energy Strengthens Presence in Arizona with Local Leadership and Proven Expertise
07:00am, Wednesday, 05'th Nov 2025
PHOENIX--(BUSINESS WIRE)--Albireo Energy, a leading independent provider of building automation and energy services, today announced the continued growth of its Arizona Division and the appointment of
Albireo Energy Launches Private Cloud Services to Enhance Building System Data Security and Performance
07:00am, Monday, 27'th Oct 2025
EDISON, N.J.--(BUSINESS WIRE)--Albireo Energy, a leading independent building controls and energy services provider and a Huron Capital portfolio company, today announced the launch of Private Cloud S
Albireo Launches Critical Alarm Management Service for Mission Critical Buildings that Require Uptime and Reliability
08:00am, Monday, 06'th May 2024
EDISON, N.J.--(BUSINESS WIRE)-- #BAS--Albireo Energy, a leading independent building controls and energy services provider, and Huron Capital portfolio company, today announced the launch of Critical
Albireo Energy Sees Buildings in a Different Way as it Unveils New Brand Identity
08:00am, Thursday, 14'th Dec 2023
EDISON, N.J.--(BUSINESS WIRE)-- #BuildingSystemsPerformance--Albireo Energy, a leading independent building controls and energy services provider and Huron Capital portfolio company, revealed its new
Is Albireo Pharma (ALBO) Stock Outpacing Its Medical Peers This Year?
11:18am, Wednesday, 01'st Mar 2023
Here is how Albireo Pharma (ALBO) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations
11:51pm, Monday, 30'th Jan 2023
NEW YORK , Jan. 30, 2023 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights
Albireo Pharma: Elucidating The Ipsen Buyout (Rating Upgrade)
02:19pm, Tuesday, 10'th Jan 2023
Albireo Pharma, Inc. has entered into an agreement to get acquired by Ipsen. Bylvay is already approved for PFIC. Nevertheless, the stellar drug is poised to gain additional labels for Alagille syndro
2 Tiny Nasdaq Stocks Making Major Merger Moves Monday
11:00am, Monday, 09'th Jan 2023
The market is moving higher, and these small companies are helping.
Albireo Pharma, Inc. (ALBO) Q3 2022 Earnings Call Transcript
08:35pm, Tuesday, 08'th Nov 2022
Albireo Pharma, Inc. (NASDAQ:ALBO ) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET Company Participants Hans Vitzthum - Managing Director, LifeSci Advisors Ron Cooper - President and Chie
Albireo Pharma (ALBO) Reports Q3 Loss, Tops Revenue Estimates
06:48pm, Tuesday, 08'th Nov 2022
Albireo Pharma (ALBO) delivered earnings and revenue surprises of -1.61% and 1.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Albireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022
08:30am, Tuesday, 01'st Nov 2022
– Oral late breaker with new results from positive Phase 3 ASSERT study in Alagille syndrome (ALGS)
Albireo to Report Q3 2022 Financial Results on November 8, 2022
08:30am, Monday, 31'st Oct 2022
Conference call and webcast to be held at 4:30 pm ET Conference call and webcast to be held at 4:30 pm ET
Albireo: Strong Phase 3 Data Foretells More Upside
06:44pm, Wednesday, 12'th Oct 2022
Sales for Bylvay's first approved indication is increasing. The company recently posted superb data for an orphan disease known as Alagille Syndrome.
